Navigation Links
Melior Enters Research Collaboration with AstraZeneca
Date:8/19/2008

Melior Discovery, Inc. announced today that it has signed an agreement with AstraZeneca PLC under which Melior’s in-vivo theraTRACE indications discovery platform will be used to evaluate the therapeutic activity of selected AstraZeneca compounds.

EXTON, Pa. (Business Wire EON) August 19, 2008 -- "Our agreement represents a significant opportunity for Melior to deliver value to AstraZeneca through the application of our unique and innovative in vivo testing platform," said Andrew Reaume, PhD, President and CEO of Melior. "We look forward to a productive collaboration."

Melior Discovery Overview

Melior Discovery is leading the transformation of drug repositioning with its unique theraTRACE platform of multiplexed in vivo models. Melior is using theraTRACE to both build an internal pipeline of development candidates as well as sharing this capability with pharmaceutical and biotechnology company partners. In the former case, Melior identifies and develops "privileged" compounds that have been discontinued by other companies for lack of efficacy in their original indications. Melior is also able to identify appropriate compounds for repositioning by leveraging a close working relationship with the renowned medicinal chemist, Dr. Christopher Lipinski. In its partnered arrangements, Melior offers pharmaceutical partners an approach to expand their late-stage pipelines with safe, high-quality drug candidates

Melior Discovery is located in Exton, PA.

Read the full story at http://www.prweb.com/releases/melior/astrazeneca/prweb1226754.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1

Related biology technology :

1. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
2. American Laser Centers Opens Three Minneapolis-St. Paul Area Clinics
3. Chromos enters into an Arrangement Agreement
4. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
5. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
6. Albemarle Enters Ibuprofen Agreement with Dr. Reddys
7. WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing
8. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
9. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
10. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
11. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Melior Enters Research Collaboration with AstraZeneca 
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):